Search

Displaying results 1351 - 1360 of 10000 in total
  1. Indication

    Recurrent Ulcers, Duodenal and Gastric

    go.drugbank.com/conditions/DBCOND0136040
    Drugs: Cimetidine
    Synonyms: Recurrent Ulcers, Duodenal and Gastric
  2. Indication

    Severe Vulvar and Vaginal Atrophy

    go.drugbank.com/conditions/DBCOND0142190
    Drugs: Conjugated estrogens
    Synonyms: Severe Vulvar and Vaginal Atrophy
  3. Drug

    Clofazimine

    go.drugbank.com/drugs/DB00845
    ApprovedInvestigationalWithdrawn

    treatments such as [rifampicin] and [isoniazid]. … It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids.

    Categories: dapsone, rifampicin and clofazimineProducts: FAZIM 100MG CAPSULE
  4. Drug

    Atracurium

    go.drugbank.com/drugs/DB13295
    ApprovedInvestigationalWithdrawn

    Products: ATRACURIO BESILATO 10MG/ML SOLUCION INYECTABLE
  5. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.

    Categories: Antineoplastic and Immunomodulating AgentsProducts: ALECENSA HARD CAPSULE 150MG, Alecensa (Alectinib) Hard Capsules 150mg
  6. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.

    Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: TYSABRI® SUBCUTÁNEO 150MG/ML
  7. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … Ltd. and co-developed with Roche and Genentech.[L1015]

    Categories: Amino Acids, Peptides, and Proteins, Blood and Blood Forming OrgansProducts: HEMLIBRA 150MG/ML SOLUTION FOR INJECTION, HEMLIBRA SOLUTION FOR INJECTION 150MG/ML
  8. Drug

    Vancomycin

    go.drugbank.com/drugs/DB00512
    ApprovedInvestigational

    Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. … caused by _Staphylococcus aureus_, including methicillin-resistant strains [LP1196].

    Categories: Alimentary Tract and Metabolism, Amino Acids, Peptides, and ProteinsProducts: Vancocin Cp Add-vantage Inj 500mg/vial, Eberth 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung oder zur Herstellung einer Lösung zum Einnehmen
  9. Drug

    Biperiden

    go.drugbank.com/drugs/DB00810
    ApprovedInvestigationalWithdrawn

    It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. … A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism.

    Products: AKINETON 2MG, Akineton Tab 2mg
  10. Drug

    Chlorine dioxide

    go.drugbank.com/drugs/DB12453
    Approved

    Chlorine Dioxide has been used in trials studying the treatment of Halitosis.

    Products: Disinfectant and Sanitizer, V Shield Hand Sanitizer